Ticker archive · $PHAT

$PHAT Filing Signals & Market Reactions

Delayed, SEO-crawlable recaps of AI-scored catalysts for $PHAT — including observed post-filing price moves. Live streaming stays exclusive to VIP.

? All delayed signals

$PHAT

$PHAT – Phathom Pharma Reports Q3 2026 Revenue of $84.7M (+71% YoY), Reaffirms Guidance

Phathom Pharmaceuticals, Inc.

2026-10-29 00:00:00 UTC · SEC_8K · All $PHAT

?? Positive AI Sentiment (+6.5 / 10)

Net revenues rose 71% YoY to $84.7M, driven by over 2M VOQUEZNA prescriptions.
GAAP net loss narrowed significantly to $0.16 per share vs. $0.41 in Q3 2025; non-GAAP EPS was positive at $0.04.
Generated positive operating cash flow for the second straight quarter; reaffirmed full-year 2026 guidance.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing ?